|Description||DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7.5 nM.|
|Synonyms||SCHEMBL16974048; MolPort-039-338-073; BDBM50015421; DY 268; AKOS027470244; 1-[(3-methoxyphenyl)methyl]-N-(4-methyl-3-morpholin-4-ylsulfonylphenyl)-3-(4-methylphenyl)pyrazole-4-carboxamide|
|Solubility||DMSO: 100 mM|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
PX-102, also known as PX-20606, is a farnesoid X-activated receptor (FXR) agonist. PX-102 is indicated to be active in lowering plasma cholesterol, and ameliora...
PX102 is a Farnesoid X-activated Receptor (FXR) agonist originated by Phenex Pharmaceuticals. PX102 demonstrated potent plasma cholesterol-lowering activity tha...
PX 20350 is a farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FX...
DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7...
Fexaramine is a small molecule farnesoid X receptor agonist with 100-fold increased affinity relative to natural compounds.
Tropifexor is a novel highly potent agonist of farnesoid X receptor (FXR), which regulates bile acid metabolism and signaling. FXR activated by Tropifexor can i...
INT-767, a steride compound, has been found to be a inhibitor of FXR and TGF5 and could have probable effect against some liver and metabolic diseases. It was j...
LY2562175 is a potent and selective FXR agonist in vitro. It has robust lipid modulating properties, lowering LDL and triglycerides while raising HDL in preclin...